Ligand Pharmaceuticals Inc
NASDAQ:LGND

Watchlist Manager
Ligand Pharmaceuticals Inc Logo
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Watchlist
Price: 196.08 USD -0.23% Market Closed
Market Cap: 3.9B USD
Section:
 

Relative Value

The Relative Value of one LGND stock under the Base Case scenario is 104.67 USD. Compared to the current market price of 196.08 USD, Ligand Pharmaceuticals Inc is Overvalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LGND Relative Value
Base Case
104.67 USD
Overvaluation 47%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

15.3
P/S
P/S
Price to Sales
15.3
vs History
3
vs Industry
38
Median 3Y
11.2
Median 5Y
7.7
Industry
8.2
Forward
15.1
More Details
79.3
P/E
P/E
Price to Earnings
79.3
vs History
1
vs Industry
8
Median 3Y
36.4
Median 5Y
24.7
Industry
24.2
Forward
26.3
More Details
120.8
P/OCF
P/OCF
Price to OCF
120.8
vs History
1
vs Industry
8
Median 3Y
26.9
Median 5Y
25.3
Industry
23
More Details
7.9
P/FCFE
P/FCFE
Price to FCFE
7.9
vs History
30
vs Industry
9
Median 3Y
7.9
Median 5Y
-7.4
Industry
25.5
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
1
vs Industry
35
Median 3Y
2.1
Median 5Y
1.9
Industry
3.3
More Details
14.5
EV/S
EV/S
Enterprise Value to Sales
14.5
vs History
3
vs Industry
36
Median 3Y
9.6
Median 5Y
6.5
Industry
8.6
Forward
14.2
More Details
15.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.3
vs History
3
vs Industry
37
Median 3Y
10.3
Median 5Y
8.5
Industry
10.5
More Details
57.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
57.7
vs History
6
vs Industry
5
Median 3Y
26.1
Median 5Y
18.2
Industry
6.1
Forward
33.4
More Details
126
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
126
vs History
17
vs Industry
2
Median 3Y
69.8
Median 5Y
29.6
Industry
6.6
Forward
72.4
More Details
113.9
EV/OCF
EV/OCF
Enterprise Value to OCF
113.9
vs History
1
vs Industry
10
Median 3Y
22.9
Median 5Y
22.8
Industry
8.8
More Details
118.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
118.2
vs History
1
vs Industry
8
Median 3Y
10.5
Median 5Y
14.4
Industry
6.8
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
1
vs Industry
35
Median 3Y
2.3
Median 5Y
1.8
Industry
5.7
More Details

Multiples Across Competitors

LGND Competitors Multiples
Ligand Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
3.9B USD 15.3 79.3 57.7 126
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS 61 215 173.5 -4 203 864.2 -4 125 277.8 -4 116 095
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 170 980.7 -162 409.6 -197 217.1 -194 966.6
US
Abbvie Inc
NYSE:ABBV
382.8B USD 6.4 163 15.9 22.5
US
Amgen Inc
NASDAQ:AMGN
175.6B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
153.4B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 9.6 30.7 22.5 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.7 -526.1 -572.9 -557.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84.9B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.8B EUR 13.8 32.4 55.6 57.2
P/S Multiple
Revenue Growth P/S to Growth
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average P/S: 8 671 661.9
15.3
24%
0.6
IL
C
Can Fite Biopharma Ltd
TASE:CANF
61 215 173.5
140%
437 251.2
FR
Pharnext SCA
OTC:PNEXF
34 170 980.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 061.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average P/E: 48.2
79.3
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 203 864.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 409.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
163
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.4
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average EV/EBITDA: 26.5
57.7
59%
1
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 125 277.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.6
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Average EV/EBIT: 36.8
126
94%
1.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 116 095 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 966.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
57.2
N/A N/A

See Also

Summary
LGND intrinsic value, competitors valuation, and company profile.
DCF Valuation
LGND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LGND stock valuation using valuation multiples.
Wall Street Estimates
LGND price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LGND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.